Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 27-34

  Wigal, Sharon B ^a   Jun, Angela ^a   Wong, Amanda A ^a   Stehli, Annamarie ^a   Steinberg Epstein, Robin ^a   Lerner, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; Amphetamine; Cardiac risk factors; LDX; Safety

Indexed keywords

LISDEXAMFETAMINE; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BASOPHIL; BEHAVIOR DISORDER; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CALCIUM BLOOD LEVEL; CARBON DIOXIDE BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CHILD; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAPHY; ELECTROLYTE BALANCE; EOSINOPHIL COUNT; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERFOCUS; IRRITABILITY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOCYTE; MOODY; NEUTROPHIL COUNT; OPEN STUDY; POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; PR INTERVAL; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PULSE PRESSURE; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REVIEW; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SODIUM BLOOD LEVEL; STOMACH PAIN; SUCKING LIP; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TALKATIVE; THROMBOCYTE COUNT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VITAL SIGN; VOMITING; XEROSTOMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; SYSTOLE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; SYSTOLE; TACHYCARDIA;

EID: 78049520423     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2198     Document Type: Review

References (23)

1. Shire US Inc. Adderall XR [package insert]. Wayne, PA: Shire US Inc; 2010.
2. McNeil Pediatrics. Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2008.
3. Novartis Pharmaceuticals Corp. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
4. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008;29(4):335.
5. Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? Paediatr Drugs. 2010;12(3):165-175.
6. Perrin JM, Friendman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Section on cardiology and cardiac surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-453.
7. Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002; 109(3):e39-e45.
8. Wigal SB, Wilens TE, Wolraich M, Lerner M. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results. Pediatrics. 2007;120(1):e120-e128.
9. US Food and Drug Administration. FDA approval letter. Drug approval package: Vyvanse (lisdexamfetamine dimesylate) NDA. #021977. US Food and Drug Administration. 2007. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021977s000TOC.cfm. Accessed May 29, 2009.
10. Shire US Inc. ADHD medicine: Vyvanse (lisdexamfetamine dimesylate) CII dosing information. http://www.vyvanse.com/dosing.asp. Accessed April 3, 2009.
11. Wigal SB, Maltas S, Crinella F, et al. Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children with attention deficit hyperactivity disorder. In press. J Atten Dis.
12. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327.
13. Wigal SB, Wong AA, Jun A, Stehli A, Steinberg-Epstein R, Lerner MA. Adverse events in medication treatment naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate. In press.
14. Cascade E, Kalali AH, Wigal SB. Real-world data on attention deficit hyperactivity disorder medication side effects: expert commentary. Psychiatry. 2010;7(4):13-15.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR). Washington, DC: American Psychiatric Association; 2000.
16. Kaufman AS, Kaufman NL. KBIT-2: Kaufman Brief Intelligence Test, Second Edition. Minneapolis, MN: NCS Pearson; 2006.
17. DuPaul GJ, Power TJ, McGoey KE, Ikeda MJ, Anastopoulos AD. ADHD Rating Scale IV: Checklists, Norms and Clinical Interpretation. New York, NY: Guilford; 1998.
18. Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988.
19. Wigal S, Wigal T. The Laboratory School Protocol: its origin, use, and new applications. J Attent Disord. 2006;10(1):92-111.
20. Wigal SB, Kollins SH, Childress AC, Squires L; 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.
21. Biederman J, Boellner SW, Childress AC, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-976.
22. Biederman J, Krishnan S, Schreckengost J, Findling RL. Comparative efficacy and safety of lisdexamfetamine dimesylate in stimulant-naïve and previously treated children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. Abstract presented at: American Psychiatric Association Annual Meeting, May 19-24, 2007; San Diego, CA.
23. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ. 2001(7292);322:989-991.